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Abstract. Probiotic Escherichia coli Nissle 1917 (EcN) is a good 
colonizer of the human gut and its efficacy in the inflammatory 
process undergone in ulcerative colitis has been demonstrated. The 
probiotic action is mainly through the modulation of intestinal 
epithelial tight junctions and immune system. Here we review the role 
of outer membrane vesicles (OMVs) released by this probiotic strain 
on the modulation of intestinal homeostasis.  EcN OMVs enter into 
host epithelial cells via clathrin-mediated endocytosis and are sorted to 
lysosomes via endocytic compartments. In cellular models of 
intestinal barrier, EcN OMVs stimulate the underlying immune 
system through the intestinal epithelium, triggering immune and 
defense responses. Thus, the use of probiotic derived OMVs could be 
a safe probiotic-derived strategy targeting intestinal inflammatory 
processes.              
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Introduction 
       
      In the mammalian gut, bacteria are not in direct contact with the 
epithelium due to the mucin layer that covers the intestinal mucosa. In fact, a 
compact inner mucin layer, which is impenetrable to bacteria, physically 
separates microbiota and host epithelial cells. Thus, the crosstalk between 
microbiota and the host mainly relies on secreted factors that can go through 
the mucus layer, reach the epithelium and activate cell signalling pathways 
that modulate host immune and defence responses such as secretion of 
cytokines or antimicrobial peptides, mucus production or regulation of 
intercellular intestinal junctions [1,2]. Bacterial secreted factors can be 
released into the extracellular milieu as free-soluble compounds or included 
in membrane vesicles.  
 All bacteria, either commensal or pathogenic strains, have evolved 
different systems to contact and communicate with host cells. One strategy is 
the formation of membrane vesicles that can deliver the cargo to distant 
targets in the host. In fact, membrane vesicles are considered intercellular 
communicasomes. 
 Here we give a view of the intestinal microbiota and especially in the 
vesicles released by Gram-negative bacteria, which are known as outer 
membrane vesicles (OMVs). We review the modulation of the intestinal 
barrier and the immune response provided by membrane vesicles secreted by 
the gram-negative probiotic Escherichia coli Nissle 1917. 
  
1. Gut microbiota 
 
 The mammalian intestine is one of the most densely colonized 
ecosystems. The whole of the microorganisms that inhabit the intestine 
constitute the so-called intestinal microbiota, which is formed by between 
500 and 1000 microbial species, mostly anaerobic and anaerobic facultative 
bacteria. Human gut microbiota constitutes a biomass of 1.5 kg shaped by 
10
14
 microorganisms [3], thus outnumbering the total host cells by an 
estimated 10-fold. The microbiota has an enormous metabolic capacity and 
carries a repertory of genes that exceeds by more than 100 times the genetic 
information of the host. The concentration and the variety of microorganisms 
increase throughout the gastrointestinal tract, being the colon the most 
densely colonized section [4]. 
 Gut microbiota plays important roles that are crucial for the function of 
the intestine and host survival. Therefore, it has been considered as an organ 
that acts synergistically with the host [5]. In this context, microbiota 
plays metabolic functions mainly associated with energy recovery, synthesis 
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of vitamins and fermentation of non-digestible compounds, which 
metabolism produces short chain fatty acids that have a positive influence on 
the differentiation and proliferation of the intestinal epithelium. Gut 
microbiota also provide important protective functions related with 
displacement of pathogens, either by competing for nutrients and specific 
receptors, or through expression of anti-microbial factors. Finally, gut 
microbiota has relevant structural functions that control the integrity of the 
intestinal barrier and it is essential for the development and normal function 
of the host immune system [6]. 
 
2. Gut microbiota-host communication 
 
 The communication between the microbiota and the host occurs at the 
intestinal mucosa, which is complex and structured in three components: the 
mucus layer, the epithelial cell barrier and the intestinal immune system. 
 The mucus layer that covers the gastrointestinal tract is organized in two 
layers at the colon level. The inner layer (50-200 μm thick) is firmly attached 
to the epithelium and consists of a compact structure formed by stacked 
mucin polymers in which bacteria cannot penetrate. The outer mucus layer is 
looser and is the habitat for commensal bacteria.  
 Epithelial cells that form a monolayer that separates the external 
environment from the host internal medium constitute the second layer of 
defence. This epithelium is mainly formed by enterocyte-type cells, which 
are the absorptive cells, and by other specialized cell types such as goblet 
cells, responsible for mucus secretion. M cells detect bacteria that have 
surpassed the internal mucus layer, phagocyte and translocate them to the 
lamina propria where a local immune response is triggered in order to 
eliminate the microorganism or induce tolerance. Paneth cells are specialized 
epithelial cells that secrete peptides with antimicrobial activity. This layer of 
epithelial cells constitutes a dynamic physical barrier. Adjacent cells in the 
monolayer are interconnected by different types of intercellular junctions; of 
special interest are the tight junctions (TJ), which regulate the permeability 
of the intestine helping to maintain a strict and regulated separation between 
the organism and the intestinal lumen. In addition, the intestinal epithelial 
cells must signal to the underlying immune system in response to luminal 
bacteria.  
 The third component of the intestinal mucosa is the immune system 
formed by the lymphoid tissue associated to the intestine. Specifically, the 
immune cells of the lamina propria coordinate the development of innate and 
adaptive responses that allow a state of tolerance to food antigens and 
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commensal microbiota and trigger specific mechanisms to eradicate 
pathogens [7]. 
 The interaction between the microbiota, the intestinal epithelium and the 
host immune system is essential for host homeostasis. Changes in microbiota 
population can have harmful impact on human health. Many factors 
(infections, genetics, environment, diet, reduced physical activity) may lead 
to imbalances or shifts in microbiota composition, a concept known as 
dysbiosis. This condition has been linked to gastrointestinal disorders caused 
by bacterial or viral infections, and also to metabolic (obesity, insulin 
resistance, hepatic steatosis) and immunological diseases (allergies, 
autoimmune diseases or inflammatory diseases) [8,9].  
 
3. Probiotics in gut homeostasis 
 
 The administration of probiotics is one of the approaches in the 
treatment of intestinal disorders, especially those associated with microbiota 
imbalance and homeostasis alteration. These approaches are aimed to restore 
the initial equilibrium and to regain the integrity of the intestinal barrier and 
the health status of the individual.  
 Probiotics are defined as “live microorganisms that, when administered 
in adequate amounts, confer a health benefit on the host” (WHO and FAO 
2006). To be considered a probiotic, the strain should not have human 
pathogenic effects, be able to survive during the intestinal transit, be a good 
colonizer of the gut mucosa, diminish pathogen adherence to cell surface and 
invasion, and display antimicrobial properties against pathogens. Besides all 
these characteristics, the probiotic must be accompanied by beneficial effects 
on the host at different levels such as on the intestinal barrier function, 
intestinal immune system and on the microbiota itself [8]. Concerning 
intestinal barrier function, the action can be directed to several targets. One 
mechanism is the strengthening of the epithelial barrier through the 
regulation of the expression of TJ proteins or their redistribution inside the 
cell. Other mechanisms are related with the expression of molecules that 
interfere with pathogens such as adhesins that allow adhesion of the 
probiotic to intestinal mucosa diminishing pathogen adhesion by competitive 
exclusion, or secreting anti-microbial peptides that inhibit pathogen growth 
or survival. A probiotic may also modulate the host immune system.  
 However, it is important to note that not all these properties are found in 
all probiotics. Thus, each probiotic has individual mechanisms of action, 
which differ from those of other strains and confer its specific 
characteristics. This explains why a probiotic strain is useful to treat a 
specific pathology but not others. However, it has been proposed that some 
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mechanisms could be highly widespread among the probiotic genera while 
others are strain-specific. 
 Most of the widely used probiotics are Gram-positive bacteria from the 
genus Lactibacillus or Bifidobacterium. Besides, the Gram-negative strain 
Escherichia coli Nissle 1917 (EcN) is a well-studied probiotic used in the 
treatment of intestinal diseases. 
 
3.1. Escherichia coli Nissle 1917 (EcN) 
 
 This Gram-negative bacterium belongs to the Enterobacteriacea family 
and is included in the E. coli B2 phylogenetic subgroup. This strain was 
isolated by Alfred Nissle in 1917 from the stool of a soldier who survived a 
shigellosis outbreak during the First World War. It is currently 
commercialized as a probiotic for the treatment of dysbiosis and intestinal 
inflammatory bowel diseases in Germany with the trade name of Mutaflor® 
and in Italy as EcN®. The use of this probiotic has been particularly 
recommended for the prevention of diarrheal diseases caused by pathogens 
such as Shigella, Salmonella or E. coli, and for the treatment of ulcerative 
colitis. In fact, various clinical trials have proved its therapeutic benefits in 
inducing and maintaining remission of this inflammatory disease [10].  
 A number of studies have been carried out to characterize the properties 
of EcN, both at the phenotypic and genetic levels. This probiotic is a good 
colonizer of the human gut and positively affects gastrointestinal 
homeostasis and microbiota balance, as it promotes anti-inflammatory 
modulation of the immune response and reinforces the function of epithelial 
barrier through the positive regulation and redistribution of the TJ proteins. 
EcN has GRAS status (generally recognized as safe). Several factors 
contribute to its safety, such as the expression of a semi-rough 
lipopolysaccharide (LPS) with shortened O6 side chains that confers this 
probiotic sensitivity to serum. This probiotic does not produce known toxins, 
but several adhesins and fimbriae that allow this probiotic to effectively 
compete with pathogens for the binding sites in the host intestine. The EcN 
genome has been sequenced (genome size 5,441,200 bp) and is estimated to 
contain 5,324 coding sequences, being about 108 genes strain-specific 
[11,12]. Comparative genomic analyses indicate that EcN arises from of an 
uropathogenic ancestor like E. coli strain CFT073 and that through 
evolutionary processes has lost virulence factors and gained genes that 
confer to this strain the probiotic properties [13]. In this context, EcN 
expresses a wide repertoire of fitness factors that promote its 
competitiveness, a fact that can probably explain its success as a probiotic.  
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 Within the fitness factors there are microcins, iron uptake systems, 
adhesins and proteases that help intestinal colonization [14,15]. EcN encodes 
six different iron transport systems that are advantageous for competing with 
other intestinal bacteria for the acquisition of iron within the gastrointestinal 
tract, in which this metal is limiting. In addition, this probiotic strain 
expresses several adhesins such as FimA, F1C and curli that help biofilm 
formation and contribute to EcN adhesion to intestinal mucosa and, 
therefore, the colonization and persistence in the intestinal tract [16]. 
 Regarding the immunomodulatory effects, EcN modulates the host 
immune system by promoting a decrease in proinflammatory cytokines IL-2, 
TNF-α, IFNγ and an increase in anti-inflammatory cytokines like IL-10. This 
probiotic can reduce intestinal inflammation by downregulating expansion of 
newly recruited T cells into the intestinal mucosa. In this situation, resident 
activated intestinal T cells allow elimination of deleterious antigens, and 
hence contribute to maintaining immunological homeostasis [17]. On the 
other hand, the structural protein of the EcN flagellum, flagellin H1, is 
recognized by the immune receptor Toll-like receptor-5 (TLR5) on the 
epithelial host cell membrane. This interaction activates the downstream 
signaling pathway that triggers secretion of interleukin (IL) -8 (IL-8), a 
relevant cytokine that acts as a chemoattractant of neutrophils, ensuring the 
phagocytosis of pathogens in situ. Flagellin H1 also activates the host 
defense response to counteract adhesion and invasion of pathogens by 
increasing the synthesis of the inducible antimicrobial peptide β-defensin-2 
(hBD-2) [18]. This antimicrobial peptide has a large spectrum of action 
being active against Gram-negative and Gram-positive bacteria, yeasts and 
virus. Additionally, EcN expresses on its cell surface a capsular 
polysaccharide, named K5 antigen, typical of pathogenic E. coli strains of 
the urinary tract and other strains causing extraintestinal infections. This 
capsule mediates the interaction of EcN with enterocytes and induces the 
expression of various chemokines such as the monocyte chemoattractant 
protein-1 (MCP-1), CCL5 (or RANTES) that recruits T cells, eosinophils 
and basophils, the macrophage inflammatory proteins 2-alpha and 2-beta 
(MIP- 2α and MIP-2β) and interferon-γ (IFN-γ). The loss of this capsular 
polysaccharide drastically reduces the level of chemokine induction after 
interaction with the host [19]. 
 Within the modulatory effects, this probiotic is able to improve the 
intestinal epithelial barrier by strengthening TJs between adjacent epithelial 
cells. In vivo and in vitro studies have revealed that EcN promotes increased 
expression of the zonula occludens (ZO)-1 and ZO-2 proteins [20,21], 
although the microbial factors mediating these effects are not still known. 
More recently, it has been described that EcN mediates positive regulation of 
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the TJ protein claudin-14, and this effect has been attributed to the secreted 
TcpC protein [22]. 
 The probiotic effect of EcN has been attributed to the combination of 
several properties that include particular fitness factors, interference factors 
and immunomodulatory properties [23]. However, despite the successful 
therapeutic applications of EcN the bacterial effectors and molecular 
mechanisms responsible for its beneficial effects are not always well-known.  
 
4. Bacterial vesicles in host-microbiota cross-talk 
 
 OMVs are spherical membranous structures with an average diameter 
between 20 to 300 nm in size, which bud and detach from the cell during 
active growth. They contain a big range of bacterial molecules and 
compounds such as LPS, outer membrane proteins, periplasmic and 
cytosolic proteins, virulence factors, DNA, RNA and lipids. Thus, unlike 
other secretion systems, OMVs allow transfer of a diverse range of 
biochemically active molecules to proximal cells in a protected form. In the 
mammalian gut, OMVs are able to diffuse through the mucin layer, reach the 
intestinal epithelium and modulate its function and also control the innate 
and adaptive immune responses [24,25,26,27].  
 OMVs are released during all stages of bacterial growth in numerous 
media and conditions including natural environments such host fluids and 
tissues. They are originated from the outer membrane bacterial envelope, 
whose architecture is basic to understand vesicle biogenesis. The envelope of 
Gram-negative bacteria is formed by two membranes, the outer membrane 
and the cytoplasmic membrane, separated by the periplasmic space. These 
structures contain proteins that have key roles, such as nutrient acquisition, 
bacterial adhesion, secretion, signalling and protection against the external 
environment [28]. The mechanisms that lead to OMVs biogenesis are still 
poorly understood, although it is known that multiple processes seem to be 
involved, being destabilization of the membrane integrity a crucial factor 
[29]. All models proposed for OMVs biogenesis depend on an initial 
decoupling of the outer membrane from the peptidoglycan (PG) layer by 
disruption of the crosslinks between PG and the lipoproteins Pal and Lpp. 
This promotes the curvature of the outer membrane, leading to vesicle 
formation. Vesiculation can be also altered by factors such as temperature, 
nutrient availability, oxidation, quorum sensing and antibiotics [28].  During 
biogenesis, OMVs acquire a vast number of compounds, which are 
important for bacterial survival and for the interaction with the host [27]. 
However, the pathways by which OMVs include their cargo remain 
unknown [28,30].  
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 Many studies carried out with Gram-negative pathogens showed that 
OMVs are internalized into host cells and contribute to virulence by 
delivering cytotoxic factors and mediators that interfere with the immune 
system [24,31,32]. Nowadays, microbiota-derived vesicles are seen as key 
players in signaling processes in the intestinal mucosa [33,34]. However, 
studies in this field are still limited, being the first reports focused on 
Bacteroides fragilis [35,36], a main Gram-negative group in the 
gastrointestinal tract of mammals. OMVs from this commensal promote 
immunomodulatory effects and ameliorate colitis in mouse models. The 
beneficial effects are in part mediated by the capsular polysaccharide A 
(PSA) through TLR-2, although in dendritic cells OMVs from this 
microbiota strain trigger changes in gene expression that are PSA-
independent. Other studies reported the ability of Akkermansia muciniphila 
OMVs to protect the progression of induced colitis in mice [37]. Regarding 
Gram-positive bacteria, studies performed with Bifidobacterium bifidum 
LMG13195 showed that membrane vesicles from this probiotic activate 
the maturation of dendritic cells, triggering a regulatory T cells response 
[38]. 
 
5. OMVs released by the probiotic EcN modulate intestinal 
immune and defense responses 
  
 In the field of microbiota-derived vesicles, studies have been focused 
on OVMs released by the probiotic strain EcN and by commensal E. coli 
strains. Bacterial OMVs are isolated from culture supernatants and 
examined by transmission electron microscopy after negative staining  
(Fig. 1A). 
 
5.1.  Proteome of EcN OMVs  
 
 We approached proteomic analysis to identify the protein content of 
EcN OMVs [39]. This study was the first report of the vesicular proteome 
of a probiotic strain. By means of 1D SDS–PAGE and highly sensitive                 
LC–MS/MS analysis, 192 EcN vesicular proteins were identified with high 
confidence in three independent experiments. In general, the identified 
proteins provide functions related with bacterial survival and interaction 
with the host, similarly to other bacterial vesicles [40]. Interestingly, of the 
192 proteins, 18 were encoded by strain-linked genes and around 21% had 
not been previously described in bacterial vesicles. The EcN specific 
proteins are involved in the adhesion to the host tissues (fimbriae), immune 
modulation or bacterial survival in host niches (proteases, iron uptake 
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systems). Thus, these proteins may facilitate the colonization of the human 
gut. For instance, the presence of components of multiple iron uptake 
systems in EcN OMVs may allow the probiotic strain to outgrow 
commensal bacteria and compete with pathogenic strains that use similar 
siderophores for iron uptake. Concerning the identified proteases Pic and 
Sat, these proteins are typically associated to pathogens. Although the 
specific role in the probiotic strain has not been elucidated, it seems that 
they may act as fitness factors rather than virulence factors [41]. In this 
sense, Pic has been shown to promote intestinal colonization, 
hypersecretion of mucus and modulation of the host immune response 
[42]. 
 In addition to the strain-related proteins, other identified proteins may 
contribute to the beneficial effects of this probiotic. These are proteins also 
found in OMVs isolated from Gram-negative pathogens (57 common 
proteins out of 192 total identified proteins). These common proteins may 
allow bacterial establishment and persistence in host tissues, which is an 
essential issue for the activity of both probiotic and pathogens. This common 
protein group contains fitness factors that allow bacterial survival in the host, 
including periplasmic proteins that help nutrient sensing  (transport systems 
for amino acids, carbohydrates or inorganic ions), antimicrobial enzymes to 
kill competing bacteria (murein hydrolases), surface proteins that promote 
adhesion to host tissues, and factors able to modulate the host immune 
response (FlgE and FlgK). Interestingly, this common group is mainly 
formed by cytoplasmic proteins, most of them metabolic enzymes. They are 
moonlighting proteins that, depending on the cell location, can play different 
roles. Thus, in addition to the metabolic role, the secreted proteins play a 
function that contributes to gut colonization or modulation of the host 
immune response. A well-studied moonlighting protein is glyceraldehyde-3-
phosphate dehydrogenase [43,44,45,46].    
 Regarding the proteins identified for the first time in bacterial vesicles, 
the in silico functional analysis revealed that they may also contribute to 
OMVs functions that are essential in the context of this probiotic strain. An 
example is the porin NanC, whose expression is induced by                                   
N-acetylneuraminic acid, one of the most abundant sialic acids on the 
eukaryote cell membrane. The ability to use sialic acids as carbon and 
nitrogen sources may help EcN to colonize and persist in the intestinal tract.  
 This proteomic study [39] revealed that EcN OMVs are equipped with a 
wide variety of proteins related with adhesion, immune modulation and 
bacterial survival in host niches. Therefore, these proteins may contribute to 
vesicle targeting to particular host tissues and mediate the probiotic 
beneficial effects on intestinal function.  
Josefa Badia et al. 28 
5.2. Internalization of EcN OMVs by intestinal epithelial cells  
 
 Uptake of OMVs by epithelial host cells is mainly mediated by 
endocytosis. The endocytic pathway depends on the composition and cargo 
of the vesicles. The two main pathways involved in OMVs internalization 
are clathrin-mediated endocytosis and lipid raft-dependent endocytosis. 
These pathways create endosomal compartments with different surfaces 
that allow the delivery of vesicle components to various subcellular 
destinations.  
 Many studies dealing with internalization of bacterial OMVs have 
been carried out with vesicles from Gram-negative pathogens. However, 
regarding microbiota or probiotic-derived OMVs, contribution to this field 
is restricted to studies performed with the probiotic EcN [47]. In this study 
EcN OMVs were labelled with rhodamine isothiocyanate B-R18. 
Fluorescence of this fluorochrome is quenched when inserted in bilayer 
membranes at high concentration, but when vesicles are fused with the 
host cell, the fluorescence is emitted and can be monitored using a 
microplate fluorescence reader. In this case, the intensity of fluorescence 
emitted is proportional to the amount of internalized vesicles. Following 
this experimental approach, kinetics studies performed in several intestinal 
epithelial cells (Caco-2, HT-29, HT-29-MTX) incubated with rhodamine 
B-R18-labeled OMVs showed a time-dependent increase in fluorescence, 
consistent with internalization of EcN OMVs. The presence of intracellular 
vesicles was confirmed by confocal fluorescence microscopy (Fig. 1B).  
 











Figure 1. A) Image of EcN OMVs visualized by electron microscope after 
negative staining. B) Visualization of internalized EcN OMVs in HT-29 epithelial 




  HT-29     HT-29 + OMVs 
 
 
Figure 1. A) Image of Ec  s visualized by electron microscope after negative 
staining. B) Visualizat on of internalized EcN OMVs in HT-29 epithelial cells by 
fluorescence microscopy. Cell membrane was stained in gre n and nuclei in blue. 
Internalized rhodamine B-R-18 labeled OMVs were visualized in red. (Images have 
been provided by Alexandra Cañas). 
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 Experiments performed in the presence of specific endocytosis 
inhibitors allowed the identification of the pathway responsible for the 
uptake of EcN OMVs. The inhibitors tested were the cholesterol-
sequestering drugs nystatin and filipin III that disrupt lipid rafts, and 
chlorpromazine that inhibit clathrin-mediated endocytosis. OMVs entry 
was inhibited by chlorpromazine but not by nystatin or filipin III. 
Therefore, EcN OMVs are internalized by intestinal epithelial cells via 
clathrin-mediated endocytosis. It is well known that vesicles internalized 
through this pathway are sorted to lysosomal compartments. Accordingly, 
co-localization of EcN OMVs with clathrin and specific markers of 
endosomes and lysosomes was confirmed by confocal fluorescence 
microscopy [47]. No detection of OMVs in nuclei or mitochondria was 
observed, thus EcN vesicles are likely degraded inside lysosomes. In the 
acidic endo-lysosomal compartments some specific proteins or factors are 
dissociated from the vesicles and targeted to other subcellular locations to 
trigger specific actions and cell responses [48]. Although for EcN OMVs, 
the specific function and intracellular trafficking of vesicle-derived factors 
to other organelles have not been studied so far, flow cytometry analysis of 
phosphorylated γH2AX in the nucleus of cells incubated with EcN OMVs 
showed that components released from internalized vesicles promote 
double strand breaks in the cell DNA. This effect on DNA was also 
confirmed by the formation of DNA tails in the Comet assay. The               
vesicle-associated factor responsible for this genotoxic activity has not 
been identified. Interestingly, the probiotic EcN produces colibacin, a  
non-ribosomal peptide-polyketide that induces double strand breaks in 
DNA. This peptide is synthesized by enzyme activities encoded in the pks 
island. Studies performed with an EcN mutant deficient in colibactin 
synthesis showed that, besides its genotoxic activity, colibactin is required 
for the in vivo anti-inflammatory effects of this probiotic [49]. Although 
the mechanism by which colibactin is delivered into the host cell remains 
unknown, the effects triggered by EcN OMVs on DNA suggest that 
colibactin could be delivered to mammalian cells by OMVs.  
 Despite EcN OMVs promote double strand breaks on the cell DNA, 
these vesicles do not reduce cell viability nor cause oxidative damage [47].  
 
5.3.  EcN OMVs reinforce the intestinal epithelial barrier 
 
 The intestinal epithelial layer forms a physical and biochemical barrier 
that maintains the segregation between host and intestinal microbiota. The 
function and integrity of this epithelial barrier depend on several factors, 
including the production of a mucin layer that covers the epithelial surface 
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and avoids the intimate contact with intestinal microbes, the secretion of 
antimicrobial peptides, and the formation of TJs that seal the paracellular 
space between adjacent epithelial cells. In addition, intestinal epithelial 
cells are essential to integrate microbial signals and coordinate the immune 
cell responses.  
 Recent studies have shown the ability of OMVs released by the 
probiotic EcN to reinforce the intestinal epithelial barrier by modulating 
the expression of genes encoding proteins relevant for the barrier function, 
particularly those involved in antimicrobial defense mechanisms [50] and 
the establishment of TJs [51].  
 Experiments performed with human colonic explants showed that EcN 
vesicles promote upregulation of the antimicrobial peptide hBD-2. 
Epithelial hBD-2 plays an important role in intestinal barrier function. Its 
expression is known to be induced by some probiotics, including EcN, as a 
mechanism involved in their beneficial action [52]. The induction of hBD-2 
elicited by EcN OMVs might be attributed to flagella-associated proteins 
present in these vesicles [50]. In contrast, EcN OMVs do not significantly 
modify expression of β-defensin-1 (hBD-1), an antimicrobial peptide that 
acts as a component of host innate defenses at the intestinal surface. The 
lack of vesicle-mediated effects on hBD-1 is consistent with the                 
non-regulated, high constitutive expression of this antimicrobial peptide in 
colon epithelial cells.  
 Regarding the modulation of mucus production, the probiotic EcN has 
been shown to upregulate the expression of several mucins in intestinal 
epithelial cell lines [53]. In the gut mucin-2 (MUC-2), which is secreted by 
globet cells, is of special relevance since it is the main component of the 
intestinal mucus layer. However, up-regulation of MUC-2 by EcN seems 
not to be mediated by released OMVs [50]. 
 Another mechanism by which microbiota, and especially probiotic 
strains, help to strengthen the integrity of the intestinal barrier is through 
the regulation of TJ proteins. TJs are multiprotein complexes that regulate 
the paracellular trafficking of macromolecules. They seal the adjacent 
epithelial cells in a selective permeable form and determine the apical and 
basolateral parts of the membrane and thus, cell polarity. TJs are formed 
by four types of transmembrane proteins: occludin, claudins, junctional 
adhesion molecules, and tricellulin. TJs also contain proteins ZO-1, ZO-2 
and ZO-3, which bind to claudins and act as scaffolds anchoring the TJ 
transmembrane proteins to the actin cytoskeleton. Association of the            
ZO-proteins to TJ multiprotein complexes is regulated by phosphorylation 
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mechanisms. Specific kinases control the subcellular distribution of the TJ 
proteins and by end the strength of the epithelial barrier. Claudins 
constitute a large family of TJ proteins that regulate cell permeability and 
cohesion. In humans, this family includes 27 members. Some claudins 
have a sealing function, while others act as selective channels for small 
charged molecules. The pore- forming protein claudin-2 belongs to this 
last group and greatly contributes to the transepithelial water secretion.  In 
fact, stimuli that raise claudin-2 levels result in increased barrier 
permeability. 
 Several in vitro and in vivo studies performed with live EcN bacteria 
showed that this probiotic positively modulates the intestinal epithelial 
barrier through the positive regulation and redistribution of TJ proteins           
ZO-1, ZO-2 and claudin-14 [20,21,22]. Upregulation of claudin-14 was 
attributed to the secreted protein TcpC [22]. These studies, however, did not 
reveal whether extracellular vesicles could mediate these effects. In addition, 
the TcpC secretion mechanism was unknown. With this information 
different experimental approaches were set up to assess the ability of EcN 
OMVs to strengthen the epithelial barrier in different epithelial cell lines 
[50]. To distinguish between TcpC and vesicle effects, a TcpC deficient 
mutant was derived from EcN, and OMVs were isolated from both the             
wild-type and the mutant EcN strains. The effect of OMVs on the epithelial 
barrier was confirmed by measuring the increase in transepithelial electrical 
resistance (TER) of T-84 cell monolayers at 24 h post-incubation. The 
vesicle-reinforcement effect was independent of TcpC expression. The 
positive TcpC activity on the TER was associated with the soluble secreted 
fraction. These results prove that TcpC is not secreted by OMVs. 
 The regulatory role of EcN OMVs on the expression of TJ proteins 
was analyzed measuring the mRNA (RT-qPCR) and protein levels 
(Western blot and confocal fluorescence microscopy) of ZO-1, ZO-2 and 
claudin-14 (known to be regulated by the probiotic EcN),  and also the 
leaky protein claudin-2. EcN OMVs promote up-regulation of ZO-1 and 
claudin-14, and down-regulation of claudin-2. These effects are                    
TcpC-independent (Fig. 2). Interestingly, soluble secreted TcpC also 
positively regulates the expression of ZO-1 and claudin-14, but this protein 
has no effect on the transcriptional regulation of claudin-2. Concerning 
ZO-2, results showed that vesicles released by this probiotic do not 
regulate its expression. Thus, the EcN-mediated upregulation of ZO-2 does 
not rely on secreted factors but probably depends on bacteria-associated 
components. 
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Figure 2. Modulation of the intestinal epithelial barrier by EcN OMVs in an intact 
epithelial barrier model: EcN OMVs reinforce the epithelial barrier through the 
increase of TER and positive regulation of the ZO-1 and claudin-14 proteins, as well 
as the negative regulation of claudin-2. In addition, EcN OMVs increase the 
expression of the antimicrobial peptide β-defensin-2.  
 
 Thus, contribution of EcN OMVs on the reinforcement of the intestinal 
epithelial barrier integrity, through several mechanisms, has been proved 
[51]. As stated, EcN OMVs directly modulate transcriptional regulation of 
TJ proteins, but also elicit additional responses that indirectly contribute to 
strengthen the epithelial barrier. In this sense, we have reported that OMVs 
released by this probiotic induce IL-22 expression in colonic explants [50]. 
This cytokine, mainly expressed by immune cells, targets epithelial cells 
and reinforces the intestinal barrier, thus limiting the access of microbial 
compounds and allergens to the systemic circulation.  
 
5.4. Immunomodulatory role of EcN OMVs 
 
 As commented above, EcN is a good colonizer of the human gut and 
positively affects gastrointestinal homeostasis and microbiota balance.              
In addition to its beneficial effects on intestinal epithelial barrier, this 
probiotic modulates the host immune response towards an anti-inflammatory 
balance. The EcN-mediated effects have been mainly evidenced from a great 
number of in vitro and in vivo experiments performed with live probiotic 
suspensions [17,18,20,21,54]. Nonetheless, the bacterial factors that mediate 
these effects are not always known. 
 To define whether the immune modulation effects promoted by EcN are 
mediated through released OMVs, several in vitro and ex vivo cell models 
were set up to analyze the cytokine/chemokine response elicited by EcN 
OMVs in gut epithelial and immune cells [50].  
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(i)  Direct stimulation of peripheral blood mononuclear cells (PBMCs) was 
used as an in vitro model of intestinal inflammation and barrier 
disruption. Stimulation of these immune cells with EcN OMVs 
activates the expression and secretion of IL-10, MIP1α, TNF-α, IL-6 
and IL-8. In this model of inflamed barrier, bacterial lysates also 
trigger activation of these cytokines, even to a higher extent. 
(ii) Apical stimulation of Caco-2/PBMCs co-cultures in Transwell 
permeable supports. This in vitro model that mimics intact intestinal 
barrier allows evaluating the crosstalk between OMVs, intestinal 
epithelial cells and the underlying immune cells [55,56]. In this model, 
OMVs are not in direct contact with the immune cells. Therefore, upon 
apical stimulation OMVs are internalized by epithelial cells, and 
signaling between epithelial and immune cells is produced through the 
release of soluble mediators. Apical stimulation with EcN OMVs 
results in the activation of immunomodulatory responses in the 
underlying immunocompetent cells, leading to increased secretion of 
IL-10, MIP1α, TNF-α, IL-6 and IL-8 in the basolateral compartment. 
In this model of intact intestinal barrier, bacterial lysates do not 
produce any activation effect. Parallel experiments performed in  
Caco-2 monolayers without underlying PBMCs showed that polarized 
Caco-2 cells are almost unresponsive to bacterial factors in the absence 
of crosstalk with immune cells. Overall results from this model 
indicate that released EcN OMVs can mediate the probiotic 
immunomodulatory effects in the intact intestinal mucosa. This 
mechanism may also apply to microbiota-derived vesicles. 
(iii) Stimulation of human colonic explants, an ex vivo model closer to the              
in vivo gut conditions. Results in this model confirmed the great 
potential of EcN OMVs to modulate the immune response in intact 
intestinal mucosa, being the expression profile for the cytokines 
analyzed similar to that from the in vitro co-culture model. The genes 
encoding IL-10, MIP1α, TNF-α, IL-6 and IL-8 were upregulated in 
colonic explants incubated with EcN OMVs. In addition, vesicles from 
this probiotic diminished the expression of the pro-inflammatory 
cytokine IL-12.  
 
 The study on the immunomodulatory effects of EcN OMVs [50] proved 
the ability of probiotic vesicles to mediate signaling events to the immune 
system through the intestinal epithelial barrier. Thus, the beneficial effects of 
the probiotic EcN on gut homeostasis, especially modulation of the immune 
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response and barrier function, can be mediated by released OMVs. Our 
results with probiotic vesicles can be extrapolated to the microbiota-host 
crosstalk. Release of extracellular vesicles allows microbiota to 
communicate with intestinal mucosa cells, promoting the delivery of 
mediators that trigger host immune and defense responses.  
 
6. OMVs in the treatment of intestinal inflammatory 
diseases 
 
 Inflammatory bowel diseases (IBD) are chronic gut inflammatory 
disorders that have an increasing incidence worldwide, particularly 
ulcerative colitis (UC) and Crohn’s disease. They are multifactorial 
diseases that involve a dysregulated immune response against commensal 
gut microbes in genetically susceptible individuals with altered intestinal 
epithelial integrity [57]. Conventional IBD therapies including salicylates, 
corticoids, immunosuppressants and biological agents do not always yield 
good results [58]. As a common trait, IBD patients show an altered 
intestinal microbiota balance, a condition known as dysbiosis. For this 
reason several studies have evaluated the therapeutic effect of commensal 
and probiotic strains in clinical trials [59,60] or in animal models of colitis 
[35,37,61,62,63,64]. 
 Concerning EcN, various clinical trials have evidenced its therapeutic 
benefits in inducing and maintaining remission of UC, showing similar 
anti-inflammatory effects as the standard treatment with aminosalicylate 
mesalazine [65,66]. Several mechanisms contribute to the therapeutic 
action of EcN against IBD, including the modulation of the host immune 
response toward an anti-inflammatory balance, the ability to reinforce the 
intestinal epithelial barrier [20,21,22], production of antimicrobial factors 
such as microcins and the induction of epithelial  hBD-2 [18].  
 It has been reported that EcN OMVs could mediate the                             
anti-inflammatory and barrier protection effects reported for this probiotic 
in experimental colitis [67]. In this study, oral administration of                    
EcN OMVs was evaluated in the dextran sodium sulphate (DSS)-induced 
colitis mouse model. The experimental design included pre-treatment with 
EcN OMVs for ten days before DSS intake and a final five-day recovery 
period. The OMVs-treated group received EcN vesicles during all the 
experimental period (20 days). Administration of purified EcN OMVs 
significantly reduced DSS-induced weight loss and ameliorated clinical 
symptoms and histological damage. In addition, OMVs treatment 
counteracted the altered expression of cytokines and markers of intestinal 
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barrier function, thus proving the ability of EcN OMVs to ameliorate 
mucosal injury and gut inflammation.  
 Concerning microscopic analysis of colonic samples, the OMVs-treated 
mice showed preserved goblet cells replenished with their mucin content, 
and reduced mucosal infiltration areas, ulceration and oedema. Consistently, 
values for the colonic weight/length ratio were significantly smaller in this 
treated group than in the colitic control group. All these observations are 
consistent with an improvement in the mucosal barrier integrity in mice that 
received EcN OMVs. 
 The OMV-mediated anti-inflammatory effects were clearly evidenced 
by the improvement in the exacerbated immune response associated to 
colonic damage in DSS-treated mice. This treatment activates several cells 
of the innate immune response including epithelial cells, macrophages and 
dendritic cells, which leads to upregulated expression of pro-inflammatory 
cytokines such as IL-1β, TNF-α, and IL-6, thus triggering an imbalance in     
T-regulatory cells and Th1/Th17 cell responses. This regulatory network 
facilitates sustained inflammation through activation of other cytokines such 
as IFN-γ, IL-12 and IL-17 and also reduction of the anti-inflammatory 
cytokine IL-10 [68]. This altered cytokine expression profile was 
counteracted by EcN OMVs treatment by increasing IL-10 expression and 
diminishing expression of the anti-inflammatory cytokines [67].  
 One of the first events in intestinal inflammation is the impairment of 
the epithelial barrier function. This alteration enables the access of luminal 
antigens that trigger the exacerbated immune response. Therefore, promotion 
of mucosal healing is fundamental to prevent intestinal inflammation. One 
mechanism used by EcN OMVs to protect the intestinal barrier in                  
DSS-colitic mice is downregulation of MMP-9, a metalloprotease that 
disrupt gut epithelial TJs, thus leading to increased intestinal permeability 
[69]. In addition, this treatment preserves expression of the MMP-2, which 
displays an opposite role to MMP-9 [70].  
 Another factor that contributes to mucosal barrier function is the protein 
trefoil factor 3 (TFF-3). In conditions of intestinal inflammation, such as 
DSS-induced colitis, expression of TFF-3 is downregulated [71]. 
Interestingly, EcN OMVs were able to restore the mRNA levels of TFF-3 to 
values similar to those of healthy mice. Thus, upregulation of this peptide by 
EcN OMVs contributes to epithelial protection and repair, preserving the cell 
structure of the colonic mucosa in DSS-treated mice [67]. It is known that 
TFF-3 reinforces TJs by promoting the redistribution of ZO-1 from the 
cytosol to the intercellular junctions of intestinal epithelial cells, where 
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strongly interacts with occludin, without altering ZO-1 expression [72]. 
Although EcN OMVs upregulate ZO-1 expression in several intestinal 
epithelial cell lines [51] they do not compensate the reduced ZO-1 
expression in the DSS-experimental colitis model. This may reflect that EcN 
OMVs activate different regulatory mechanisms in the presence of highly 
expressed inflammatory mediators, including those that modulate ZO-1 
location at the TJ structures, such as TFF-3. In addition to the beneficial 
effects on epithelial barrier repair, upregulation of TFF-3 may also 
contribute to ameliorate the inflammatory response in DSS-treated mice, 
since overexpression of this peptide abolishes the IL-1β mediated 
upregulation of certain pro-inflammatory cytokines [73].  
 Other markers of tissue damage and inflammation upregulated in               
DSS-induced colitis are cyclooxygenase-2 (COX-2) and inducible oxide 
nitric synthase (iNOS). These enzymes confer protection against tissue 
injury, inflammation and infection and are highly expressed at damaged 
sites. Although iNOS upregulation is part of the intestinal antibacterial 
response that results on nitric oxide (NO) production, excess NO has been 
associated with intestinal inflammation in IBD patients [74], being the 
infiltrating macrophages in intestinal mucosa the main source of upregulated 
iNOS [75,76]. In these conditions, high levels of NO may cause tissue injury 
and the mucosal lesions observed in both human IBD and mouse 
experimental colitis. In DSS-treated mice, administration of EcN OMVs 
downregulates the altered expression of both enzymes, thus contributing to 
mucosal healing [67].  
 Oral administration of OMVs isolated from the probiotic EcN 
significantly reduces colonic damage in colitic mice [67]. These vesicles 
mediate anti-inflammatory and barrier protection effects, similarly to what 
has been reported for this probiotic in experimental colitis. The components 
of EcN OMVs responsible for these effects remain unknown. The polyketide 
colibactin could be one of these mediators. It is known that colibactin is 
required for the in vivo anti-inflammatory effects of EcN [49]. Moreover, in 
the DSS-induced colitis mouse model, administration of an EcN mutant 
deficient in colibactin synthesis results in exacerbated colitis. Although the 
colibactin secretion mechanism has not been described so far, the                    
anti-inflammatory effects of EcN OMVs in experimental colitis suggest that 
colibactin could be delivered to the intestinal mucosa, at least in part, 
through released vesicles. However, the contribution of other specific 
probiotic OMV-associated factors to the modulation of mucosal healing 
markers cannot be ruled out.  
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Figure 3. Antiinflammatory and barrier protection effects of EcN OMVs in DSS-
induced experimental colitis in mice. 
 
7. Concluding remarks 
 
 The influence of microbiota in human health is well known. Nowadays, 
microbiota imbalances (dysbiosis) have been associated with great variety of 
inflammatory and metabolic diseases. A therapeutic strategy to modulate 
microbiota composition is the administration of probiotics. This therapy is 
essentially an attempt to harness the beneficial effects of commensal 
microbiota. However, translation of probiotics or microbiota-based drugs to 
human healthcare requires knowledge of the molecular mechanisms 
involved in probiotic-host interactions. Moreover, although probiotics are 
Generally Regarded As Safe, some concerns about the potential risk 
associated with their use should be considered, especially in 
immunocompromised individuals and neonates.  
 Extracellular vesicles released by microbiota have a key role in   
bacteria-host cross-talk at the intestinal mucosa, as they act as a secretion 
and delivery pathway for selected bacterial proteins and active mediators 
directly to the host cells. Studies performed with the probiotic EcN prove the 
ability of the released vesicles to mediate signalling events to the immune 
system through the intestinal epithelial barrier, thus triggering appropriate 
host immune and defence responses. In addition, EcN OMVs mediates 
intestinal anti-inflammatory and barrier protective effects in the DSS 
experimental model of colitis.  
 Interestingly, isolated OMVs are free from bacteria and can elicit the 
same effect on gastrointestinal health as the probiotic itself. Thereby,              
EcN OMVs (either alone or in combination with secreted soluble factors) 
could represent a new therapeutic treatment with a high bio-safety level to 
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prevent and ameliorate inflammatory conditions associated with intestinal 
disorders. This potential formulation fits into the term postbiotic, a group of 
new potential treatments based on probiotic or microbiota products that is 
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